Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury … – Seeking Alpha
|
Asterias Bio’s stem cell therapy shows encouraging long-term effect in Phase 1/2 study in spinal cord injury …
Seeking Alpha Asterias Biotherapeutics (AST +2.7%) announces positive results from the Phase 1/2 SCiStar study assessing AST-OPC1 in patients with subacute motor complete spinal cord injury. Results at month 12 showed 67% of those with AIS-A-categorized injury … |
Barron’s |
AveXis gets FDA nod to start pivotal gene therapy trial
BioPharma Dive The infants will be given a once-only dose of the gene therapy AVXS-101, based on one of the doses from the previous Phase 1 trial. The study could readout in 2019. AveXis anticipates starting its study in patients with SMA type 2 in the fourth quarter … AveXis, Inc. (AVXS) – Citigroup Maintains Rating And Updates Price TargetFirst News 24 |
|
Global Synthetic Biology Market share will Increase US$ 38 Billion by 2020
Medgadget (blog) Market Research Engine has published a new report titled as “Synthetic Biology Market (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) – Global Industry Analysis, Size, Share, Growth, … |
Motherboard en_us |
Scientists Used CRISPR to Edit a Gene That Causes Miscarriages
Motherboard en_us CRISPR, a fairly new gene editing tool, is changing that. While it’s still a long way from preventing miscarriages, researchers have been using the technology to generate new methods of peeking into the genetics behind infertility in hopes of more … We’re nearly ready to use CRISPR to target far more diseases | New …New Scientist Nonviral CRISPR Delivery a SuccessThe Scientist CRISPR Editing in Mice Disrupts Glaucoma-Causing Gene MutationGenomeWeb EurekAlert (press release) –agprofessional.com all 30 news articles » |
|
Study Demonstrates Potential for the Guardant360 Assay® to Predict Which Patients Will Benefit from Immunotherapy
Markets Insider REDWOOD CITY, Calif., Oct. 2, 2017 /PRNewswire/ — Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent research suggests. In a paper published in Clinical … |
New Scientist |
We’re nearly ready to use CRISPR to target far more diseases
New Scientist The race is on to edit the DNA in our body to fight or prevent disease. Promising results from animal studies targeting the liver, muscles and the brain suggest that the CRISPR genome-editing method could revolutionise medicine, allowing us to treat or … ‘CRISPR‘ Bacon: Pigs could soon save millions more livesagprofessional.com Nonviral CRISPR Delivery a SuccessThe Scientist Mammoth undertaking: CRISPR/Cas9 gene editing goes beyond medicineBioPharma-Reporter.com Guardian (blog) –wtkr.com –Scientific American all 15 news articles » |